AL
ALMDT.PA Mediantechn
- Market cap
- EUR 173M
- P/E
- -
- P/B
- 252.66x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALMDT.PA undervalued?
Graham numberThe Graham number of Mediantechn cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mediantechn fundamental analysis
4 of 11 checks passedROE 2/2
ROE surpassing expectations (1747.1%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.
ROA 0/2
The stock's ROA (-59.82%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 2/2
The stock's low PBV ratio (-9.3x) suggests it's undervalued, making it an attractive opportunity for investors.
DER 2/2
The stock has a low debt to equity ratio (-250%), which means it has a small amount of debt compared to the ownership it holds
Revenue Growth 2/2
Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.
Net Profit Growth 0/2
Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.
Assets Growth 0/2
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.
Graham Number 0/1
The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.
Dividend Growth 0/2
The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.
Dividend 0/2
The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.
Buffet Intrinsic Value 0/1
The company's stock shows signs of being overvalued (-5) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Mediantechn stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mediantechn
Median Technologies SA develops and markets software solutions and services for the use of medical images for the diagnosis and monitoring of patients with cancer in Europe, North America, and Asia. The company offers iCRO, an imaging service for oncology clinical trials; and eyonis, an end-to-end CADe/CADx software as medical devices. The company was founded in 2002 and is based in Valbonne, France.
Full company profileMediantechn financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mediantechn annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.35M | 7.69M | 6.34M | 8.95M | 13.5M | 20.5M | 23.7M | 22.2M | 22.9M | 23.4M | 47.0M |
| Gross Profit | 6.25M | 7.53M | 6.21M | 8.85M | 13.3M | 20.4M | 24.4M | -2.55M | -21.1M | 24.1M | -49.5M |
| Operating Income | -9.26M | -17.1M | -15.4M | -7.89M | -8.82M | -11.6M | -23.3M | -23.1M | -22.5M | -15.9M | -68.3M |
| EBITDA | -8.75M | -16.8M | -14.5M | -7.35M | -11.2M | -17.0M | -17.4M | -19.3M | -19.3M | -25.1M | -63.9M |
| Net Income | -9.11M | -17.2M | -15.3M | -7.99M | -12.8M | -19.3M | -20.2M | -23.0M | -25.2M | -34.1M | -108M |
| EPS | -0.66 | -1.26 | -1.15 | -0.66 | -1.06 | -1.25 | -1.28 | -1.25 | -1.36 | -0.93 | -2.21 |
| Balance Sheet | |||||||||||
| Total Assets | 46.6M | 34.1M | 18.1M | 16.1M | 25.3M | 49.4M | 34.8M | 35.9M | 24.4M | 35.9M | 77.8M |
| Total Liabilities | 7.82M | 9.21M | 9.06M | 14.8M | 36.6M | 44.4M | 42.0M | 46.2M | 58.3M | 71.0M | 80.8M |
| Shareholders' Equity | 38.7M | 24.9M | 9.09M | 1.28M | -11.4M | 4.94M | -7.25M | -10.3M | -34.0M | -35.2M | -2.99M |
| Cash & Short-term Investments | 41.9M | 28.5M | 12.8M | 7.76M | 16.4M | 39.3M | 21.7M | 19.6M | 8.29M | 18.4M | 60.8M |
| Total Debt | 459K | 4.00K | 3.00K | 1.10M | 20.2M | 16.5M | 18.2M | 23.0M | 29.4M | 21.8M | 26.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.57M | -13.8M | -15.6M | -4.39M | -5.46M | -10.1M | -15.8M | -20.2M | -17.9M | -17.4M | -36.2M |
| Capital Expenditure | 477K | 391K | 255K | 176K | 359K | 481K | 1.39M | 1.29M | 1.08M | 17.4M | 36.2M |
| Free Cash Flow | -8.05M | -14.2M | -15.9M | -4.56M | -5.82M | -10.6M | -17.2M | -21.5M | -19.0M | -18.2M | - |
| Ratios | |||||||||||
| ROE | -23.5% | -69.0% | -168.1% | -623.6% | - | -390.6% | - | - | - | - | - |
| ROA | -19.6% | -50.4% | -84.2% | -49.6% | -50.6% | -39.1% | -58.2% | -64.0% | -103.6% | -95.0% | -138.4% |
| Net Profit Margin | -143.4% | -223.9% | -241.1% | -89.2% | -95.0% | -93.9% | -85.4% | -103.4% | -110.0% | -145.8% | -229.1% |
| Debt to Equity | 0.01x | 0.00x | 0.00x | 0.86x | - | 3.34x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mediantechn dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 400K | 0.03 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Mediantechn
- Insiders 26.54%
- Institutions 11.83%
- Public & others 61.63%
- Shares outstanding 49.0M
- Free float 39.2M
Mediantechn company profile
- Company name
- Mediantechn
- Ticker
- ALMDT.PA
- ISIN
- FR0011049824
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 200
- Fiscal year end
- December
- Address
- 1800, Route des CrEtes, Valbonne, France, 06560
- Phone
- 33 4 93 33 37 77
- Website
- mediantechnologies.com
About Mediantechn
Median Technologies SA develops and markets software solutions and services for the use of medical images for the diagnosis and monitoring of patients with cancer in Europe, North America, and Asia. The company offers iCRO, an imaging service for oncology clinical trials; and eyonis, an end-to-end CADe/CADx software as medical devices. The company was founded in 2002 and is based in Valbonne, France.
Mediantechn management
7- Mr. Fredrik BragFounder, GM, CEO & Director
- Mr. Oran MudurogluPresident of Median eyonis Inc. & Chairman of the Board of Directors · born 1963
- Mr. Jean-Christophe MontignyChief Financial Officer · born 1966
- Ms. Emmanuelle LeyguesVice President of Corporate Marketing & Financial Communications
- Ms. Chrystel BrunChief Human Resources Officer
- Mr. Nicolas DanoChief Operating Officer & Chief Commercial Officer of iCRO
- Mr. Thomas BonnefontChief Operating Officer & Chief Commercial Officer ? eyonis? Business Unit